|
EORTC AISBL / IVZW |
|
|
EORTC AISBL / IVZW |
Personalised medicine: tumour analysis reveals new opportunities for existing cancer drugs. Targeted cancer therapies such as trastuzumab (Herceptin), gefitinib (Iressa) and erlotinib (Tarceva) could be used to treat a wider range of cancers than previously thought, according to new research presented today (Wednesday) at the 22nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Berlin.
Researchers map the way to personalised treatment for ovarian cancer. Researchers have shown that point mutations – mis-spellings in a single letter of genetic code – that drive the onset and growth of cancer cells can be detected successfully in advanced ovarian cancer using a technique called OncoMap. The finding opens the way for personalised medicine in which every patient could have their tumour screened, specific mutations identified, and the appropriate drug chosen to target the mutation and halt the growth of their cancer.
Scientists identify potential new target for treating triple negative breast cancer. Scientists believe they may have found a new target for treating triple negative breast cancer – one of the more difficult breast cancers to treat successfully and for which there is no targeted therapy at present.
New drug targets vitamin D receptors in hormone resistant prostate cancers: promising results from first clinical trial. A new anti-cancer drug aimed at vitamin D receptors on cancer cells has prompted encouraging responses in the levels of PSA (prostate specific antigen) in men with prostate cancer that has become resistant to hormonal therapies.
Tiny Trojan horses attack brain cancer cells. Scientists in Germany have developed a way of smuggling an anti-cancer drug past the protective blood-brain barrier and into brain tumours and metastases using a nanocarrier – a tiny capsule specially designed to pass through cell membranes and deliver its anti-cancer drug to the cancer cell.
PARP inhibitor, MK-4827, shows anti-tumour activity in first trial in humans. A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans. Some patients with a range of solid tumours, many of whom had been treated unsuccessfully for their cancer with other therapies, have seen their tumours shrink or stabilise for periods of between 46 days to more than a year. The research will be presented at the 22nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Berlin today (Thursday).
Cough medicine could help doctors identify how breast cancer patients metabolise tamoxifen, enabling them to improve individual treatments.Cough medicine could be used as way of predicting how well individual patients metabolise tamoxifen used in the treatment of their breast cancer, according to new research presented at the 22nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Berlin today (Friday).
Researchers find new target for stopping tumours developing their own blood supply: phase I trial shows first drug to inhibit ALK-1 receptor is safe and effective. Researchers have found that a newly developed drug, which is aimed at a particular receptor involved in the development of blood vessels that sustain tumour growth, is active in patients with advanced cancers and, in some cases, has halted the progress of the disease. The drug, ACE-041, targets a different molecular pathway to other anti-angiogenesis drugs and may provide a new option to treat cancer.